Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-0646
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia ; day:4 ; month:2 ; year:2020 ; pages:1-12
Investigational new drugs ; (4.2.2020), 1-12
- Urheber
-
Uy, Geoffrey L.
Assouline, Sarit
Young, Anne-Marie
Blotner, Steven
Higgins, Brian
Chen, Lin-Chi
Yee, Karen
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10637-020-00907-4
- URN
-
urn:nbn:de:101:1-2020050419330527152984
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Uy, Geoffrey L.
- Assouline, Sarit
- Young, Anne-Marie
- Blotner, Steven
- Higgins, Brian
- Chen, Lin-Chi
- Yee, Karen
- SpringerLink (Online service)
Ähnliche Objekte (12)
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene
Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis
Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
MDM2 and PARP as therapeutic targets in acute myeloid leukemia : = MDM2 und PARP als Zielstrukturen in der Therapie der Akuten Myeloischen Leukämie
Pregnancy with acute myeloid leukemia
miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia
Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143)
Current developments in acute myeloid leukemia
Treatment of Relapsed Acute Myeloid Leukemia
CDK9 inhibitors in acute myeloid leukemia
FLT3 inhibitors in acute myeloid leukemia
Precision therapy for acute myeloid leukemia
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene
Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis
Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
MDM2 and PARP as therapeutic targets in acute myeloid leukemia : = MDM2 und PARP als Zielstrukturen in der Therapie der Akuten Myeloischen Leukämie
Pregnancy with acute myeloid leukemia
miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia
Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143)
Current developments in acute myeloid leukemia
Treatment of Relapsed Acute Myeloid Leukemia
CDK9 inhibitors in acute myeloid leukemia
FLT3 inhibitors in acute myeloid leukemia
Precision therapy for acute myeloid leukemia
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene
Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis
Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
MDM2 and PARP as therapeutic targets in acute myeloid leukemia : = MDM2 und PARP als Zielstrukturen in der Therapie der Akuten Myeloischen Leukämie
Pregnancy with acute myeloid leukemia
miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia
Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143)
Current developments in acute myeloid leukemia
Treatment of Relapsed Acute Myeloid Leukemia
CDK9 inhibitors in acute myeloid leukemia
FLT3 inhibitors in acute myeloid leukemia